Biotechnology company Bluebird Bio, Inc. (NASDAQ: BLUE) received FDA approval for its gene therapy, called Zynteglo, for the treatment of beta-thalassemia in adult and pediatric patients. The treatment is possibly a cure for a rare drug disorder. In response to the FDA approval, the stock price has been climbing. Subsequently, the company revealed elaborate plans to enable rapid and affordable access to Zynteglo across the country. One-Time and Cost-Effective Gene Therapy for Thalassemia Patients Unlike standard norms, where patients with transfusion-dependent beta-thalassemia require red blood cell (RBC) transfusions every two to five weeks, Zynteglo is a one-time therapy. Although the treatment costs of $2.
https://www.tipranks.com/news/bluebird-bio-stock-price-climbing-on-fda-gene-therapy-approval?utm_source=advfn.com&utm_medium=referral
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more bluebird bio Charts.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more bluebird bio Charts.